Larimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotech company specializing in treatments for complex rare diseases, has announced its participation in two upcoming investor conferences. The company's management team will engage in one-on-one meetings with investors at:
- The Wells Fargo Healthcare Conference in Boston, MA (September 4-6, 2024)
- The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024)
These conferences provide Larimar with opportunities to connect with potential investors and showcase their progress in developing innovative treatments for rare diseases.
Larimar Therapeutics (Nasdaq: LRMR), una azienda biotech in fase clinica specializzata in trattamenti per malattie rare complesse, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Il team di gestione dell'azienda parteciperà a incontri individuali con gli investitori presso:
- La Wells Fargo Healthcare Conference a Boston, MA (4-6 settembre 2024)
- La H.C. Wainwright 26th Annual Global Investment Conference a New York, NY (9-11 settembre 2024)
Queste conferenze offrono a Larimar l'opportunità di collegarsi con potenziali investitori e mostrare i progressi nello sviluppo di trattamenti innovativi per malattie rare.
Larimar Therapeutics (Nasdaq: LRMR), una empresa biotecnológica en etapa clínica especializada en tratamientos para enfermedades raras complejas, ha anunciado su participación en dos próximas conferencias para inversionistas. El equipo de gestión de la compañía llevará a cabo reuniones individuales con inversionistas en:
- La Wells Fargo Healthcare Conference en Boston, MA (4-6 de septiembre de 2024)
- La H.C. Wainwright 26th Annual Global Investment Conference en Nueva York, NY (9-11 de septiembre de 2024)
Estas conferencias brindan a Larimar oportunidades para conectarse con inversionistas potenciales y presentar su progreso en el desarrollo de tratamientos innovadores para enfermedades raras.
라리마 치료제 (Nasdaq: LRMR), 복잡한 희귀 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사가 두 개의 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 경영진은 다음 회의에서 투자자와 일대일 미팅을 할 예정입니다:
- 웰스 파고 헬스케어 컨퍼런스 (2024년 9월 4-6일, 보스턴, MA)
- H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스 (2024년 9월 9-11일, 뉴욕, NY)
이 회의는 라리마가 잠재 투자자와 연결되고 희귀 질환 치료의 혁신적인 발전을 선보일 수 있는 기회를 제공합니다.
Larimar Therapeutics (Nasdaq: LRMR), une entreprise biotechnologique en phase clinique spécialisée dans les traitements pour les maladies rares complexes, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe de direction de l'entreprise se rencontrera pour des réunions individuelles avec des investisseurs lors des événements suivants :
- La Wells Fargo Healthcare Conference à Boston, MA (4-6 septembre 2024)
- La H.C. Wainwright 26th Annual Global Investment Conference à New York, NY (9-11 septembre 2024)
Ces conférences offrent à Larimar l'occasion de se connecter avec des investisseurs potentiels et de mettre en valeur leurs avancées dans le développement de traitements innovants pour les maladies rares.
Larimar Therapeutics (Nasdaq: LRMR), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Behandlungen für komplexe seltene Krankheiten spezialisiert hat, hat die Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Management-Team des Unternehmens wird eins-zu-eins-Meetings mit Investoren führen auf:
- Der Wells Fargo Healthcare Conference in Boston, MA (4.-6. September 2024)
- Der H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (9.-11. September 2024)
Diese Konferenzen bieten Larimar die Möglichkeit, mit potenziellen Investoren in Kontakt zu treten und ihre Fortschritte bei der Entwicklung innovativer Behandlungen für seltene Krankheiten zu präsentieren.
- None.
- None.
BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in 1x1 investor meetings at the Wells Fargo Healthcare Conference, taking place September 4-6, 2024 in Boston, MA and the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
What investor conferences will Larimar Therapeutics (LRMR) attend in September 2024?
What type of meetings will Larimar Therapeutics (LRMR) have at these investor conferences?
What is Larimar Therapeutics' (LRMR) focus as a biotechnology company?
Where is Larimar Therapeutics (LRMR) based?
